AU2015282450C1 - Benzoxazinone amides as mineralocorticoid receptor modulators - Google Patents

Benzoxazinone amides as mineralocorticoid receptor modulators Download PDF

Info

Publication number
AU2015282450C1
AU2015282450C1 AU2015282450A AU2015282450A AU2015282450C1 AU 2015282450 C1 AU2015282450 C1 AU 2015282450C1 AU 2015282450 A AU2015282450 A AU 2015282450A AU 2015282450 A AU2015282450 A AU 2015282450A AU 2015282450 C1 AU2015282450 C1 AU 2015282450C1
Authority
AU
Australia
Prior art keywords
benzoxazin
dihydro
compound
oxo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015282450A
Other languages
English (en)
Other versions
AU2015282450B2 (en
AU2015282450A1 (en
Inventor
Philip Cornwall
Karl Edman
Carl Anders Hogner
Johan Kajanus
Michael Kossenjans
Gavin O'mahony
Andrew Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2015282450A1 publication Critical patent/AU2015282450A1/en
Application granted granted Critical
Publication of AU2015282450B2 publication Critical patent/AU2015282450B2/en
Publication of AU2015282450C1 publication Critical patent/AU2015282450C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2015282450A 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators Active AU2015282450C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
US62/018,790 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
AU2015282450A1 AU2015282450A1 (en) 2017-02-02
AU2015282450B2 AU2015282450B2 (en) 2018-05-10
AU2015282450C1 true AU2015282450C1 (en) 2018-09-20

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015282450A Active AU2015282450C1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Country Status (26)

Country Link
US (2) US10017502B2 (OSRAM)
EP (1) EP3160948B1 (OSRAM)
JP (1) JP6368383B2 (OSRAM)
KR (1) KR102012222B1 (OSRAM)
CN (1) CN106536491B (OSRAM)
AR (1) AR101036A1 (OSRAM)
AU (1) AU2015282450C1 (OSRAM)
CA (1) CA2953655C (OSRAM)
CY (1) CY1121596T1 (OSRAM)
DK (1) DK3160948T3 (OSRAM)
EA (1) EA029518B1 (OSRAM)
ES (1) ES2707726T3 (OSRAM)
HR (1) HRP20190147T1 (OSRAM)
HU (1) HUE042370T2 (OSRAM)
LT (1) LT3160948T (OSRAM)
ME (1) ME03316B (OSRAM)
MX (1) MX367404B (OSRAM)
PL (1) PL3160948T3 (OSRAM)
PT (1) PT3160948T (OSRAM)
RS (1) RS58274B1 (OSRAM)
SI (1) SI3160948T1 (OSRAM)
SM (1) SMT201900039T1 (OSRAM)
TR (1) TR201900659T4 (OSRAM)
TW (1) TWI677498B (OSRAM)
UY (1) UY36195A (OSRAM)
WO (1) WO2016001631A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2707726T3 (es) * 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
CR20200224A (es) * 2019-08-30 2021-05-26 Astrazeneca Ab Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
MX2023015144A (es) * 2021-06-15 2024-01-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivados de benzoxazinona.
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CR20250112A (es) 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015259A2 (en) * 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
JP2006512357A (ja) * 2002-12-20 2006-04-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
JP2008506689A (ja) * 2004-07-14 2008-03-06 リガンド・ファーマシューティカルズ・インコーポレイテッド 細胞間受容体のモジュレーター化合物および方法
WO2007077961A2 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
GEP20115239B (en) 2006-10-31 2011-06-10 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptor antagonists
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
CA2681134A1 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
KR101477579B1 (ko) 2007-04-09 2014-12-30 다이이찌 산쿄 가부시키가이샤 피롤 유도체의 아트로프 이성체
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
UY31905A (es) * 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
BRPI1009257A2 (pt) 2009-03-12 2016-03-08 Lilly Co Eli antagonista receptor de mineralocorticoide e métodos de uso.
EP2417121A1 (en) 2009-04-10 2012-02-15 Pfizer Inc. 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
EP2569576B1 (en) 2010-05-11 2016-07-06 Koninklijke Philips N.V. Lighting module
JP2013528598A (ja) 2010-05-11 2013-07-11 ファイザー・インク ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
JP2013542255A (ja) 2010-11-10 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素
ES2707726T3 (es) * 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015259A2 (en) * 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors

Also Published As

Publication number Publication date
CA2953655A1 (en) 2016-01-07
ES2707726T3 (es) 2019-04-04
AR101036A1 (es) 2016-11-16
KR20170021883A (ko) 2017-02-28
UY36195A (es) 2016-01-08
AU2015282450B2 (en) 2018-05-10
CN106536491A (zh) 2017-03-22
KR102012222B1 (ko) 2019-10-21
SMT201900039T1 (it) 2019-02-28
PL3160948T3 (pl) 2019-04-30
MX2017000183A (es) 2017-04-25
US20170217945A1 (en) 2017-08-03
LT3160948T (lt) 2019-02-11
EP3160948B1 (en) 2018-10-24
WO2016001631A1 (en) 2016-01-07
DK3160948T3 (en) 2019-02-18
US10017502B2 (en) 2018-07-10
TWI677498B (zh) 2019-11-21
EA029518B1 (ru) 2018-04-30
CA2953655C (en) 2020-05-12
JP6368383B2 (ja) 2018-08-01
TR201900659T4 (tr) 2019-02-21
JP2017522300A (ja) 2017-08-10
EA201790046A1 (ru) 2017-08-31
ME03316B (me) 2019-10-20
TW201613909A (en) 2016-04-16
US9394291B2 (en) 2016-07-19
CN106536491B (zh) 2018-12-18
CY1121596T1 (el) 2020-05-29
PT3160948T (pt) 2019-02-01
EP3160948A1 (en) 2017-05-03
SI3160948T1 (sl) 2020-06-30
HRP20190147T1 (hr) 2019-03-22
HUE042370T2 (hu) 2019-06-28
MX367404B (es) 2019-08-20
AU2015282450A1 (en) 2017-02-02
US20150376170A1 (en) 2015-12-31
RS58274B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
AU2015282450C1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
TWI894413B (zh) 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
KR101598397B1 (ko) 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
JP5564036B2 (ja) ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体
EP3634956B1 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CA2243994A1 (en) 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production
CZ283680B6 (cs) Nové azaheterocyklylmethyl-chromany
KR20080087070A (ko) 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
EA024933B1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
DE10226943A1 (de) Phenylaminopyrimidine und ihre Verwendung
CN105073724A (zh) 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物
JP7451569B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールホモフタルイミド誘導体化合物、およびそれを含む薬剤学的組成物
EP3847170B1 (en) Novel cyclic amidine compounds for the treatment of autoimmune disease
EP2501233B1 (en) Quinazoline compounds
CA3201443A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
AU2019230859A1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
HK1237338B (en) Benzoxazinone amides as mineralocorticoid receptor modulators
HK1237338A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 JUN 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 JUN 2018

FGA Letters patent sealed or granted (standard patent)